Benzinga | Jan 10, 2022 06:18AM EST

Regeneron Pharmaceuticals Sees Prelim U.S. Net Product Sales Of REGEN-COV Of ~$5.82B For FY21; Sees Prelim U.S. Net Product Sales Of EYLEA Injection Of ~$5.79B For FY21

On January 10, 2022, at the virtual 40th Annual J.P. Morgan Healthcare Conference, Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron, are providing a corporate update.



The presentation includes information regarding the Company's preliminary (unaudited) U.S. net product sales of EYLEA(r) (aflibercept) Injection of approximately $5.79 billion for the full year 2021 (based on preliminary (unaudited) fourth quarter 2021 U.S. net product sales of EYLEA of approximately $1.54 billion).



The presentation also includes information regarding the Company's preliminary (unaudited) U.S. net product sales of REGEN-COV(r) (casirivimab and imdevimab) of approximately $5.82 billion for the full year 2021 (based on preliminary (unaudited) fourth quarter 2021 U.S. net product sales of REGEN-COV of approximately $2.29 billion).